Powered by

Allogene names ex-Adaptimmune exec Amado as CMO

Aug 05, 2019 - FierceBiotech
Board and Executive Moves

Allogene Therapeutics has named Rafael Amado as its EVP of R&D and CMO. Amado, who is set to leave Adaptimmune imminently, will join the Arie Belldegrun-founded biotech as it works to advance several allogeneic CAR-T therapies into and through clinical development.

Adaptimmune hired Amado as CMO in 2015 and expanded his responsibilities to cover its research activities last year. The positions gave Amado a central role in the progress of Adaptimmune's assets and the broader adaptive T-cell...